IM-101 120mg/mL clinical trials

A Phase 1b/2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate A) the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of IM-101 in Adult Participants with Generalized Myasthenia Gravis, and B) the Efficacy and Safety of Treatment of IM-101 in Adult Participants with Generalized Myasthenia Gravis and Ocular Myasthenia Gravis

This study is testing a new medicine, IM-101, for adults with Myasthenia Gravis (MG). It's looking at how safe it is and how well it works to improve symptoms of generalized and ocular MG.